Cosmos Health Inc. has advanced its international patent application WO2025108566A1 into the European regional phase and the national phases in the United States, Australia, and Canada. The application, titled "Hydrogel for Body Weight Management," covers proprietary hydrogel technology developed for potential applications in body weight management. The filings follow the acquisition of the patent application from Cloudpharm P.C. by Cana Laboratories S.A., a wholly owned subsidiary of Cosmos Health, on June 8, 2026.

Technology and Mechanism

The CCX0722 platform functions through a mechanical mechanism with no systemic absorption. Taken as a capsule before meals, the dried hydrogel absorbs water in the stomach and swells more than 100-fold into soft gel pieces. These pieces occupy stomach volume to support satiety before naturally passing through the gastrointestinal tract.

Development Timeline

Cosmos Health has executed a methodical development strategy for CCX0722, prioritizing long-term commercial value. Key milestones include:

Strategic Significance

The global weight management market was valued at $190.6 billion in 2025 and is projected to grow to $562.2 billion by 2033, representing a compound annual growth rate (CAGR) of 14.2%. Cosmos Health believes its outright ownership of the CCX0722 intellectual property is a differentiator, as the company controls the manufacturing platform without licensing fees or royalty-sharing obligations.

Future Outlook

The advancement of the patent application supports Cosmos Health's strategy to build an international patent portfolio around proprietary technologies. The company intends to pursue licensing, co-development, and strategic partnership opportunities for the platform. Entry into these jurisdictions does not constitute the grant of a patent, and applications will undergo examination by respective patent authorities.

Cosmos Health Inc. announced that its proprietary antiseptic solution, C-Sept PRO, has gained significant traction across leading public and private hospital groups in Greece, positioning the product as a key high-margin revenue driver. The company reported that C-Sept PRO is on track to achieve annualized sales exceeding $1.3 million, supported by a gross margin of approximately 72%. This performance underscores the product's growing acceptance and the strength of the company's infection-control portfolio in the hospital channel.

Sales Momentum and Financial Metrics

The sales trajectory for C-Sept PRO has shown consistent acceleration over the past six months. Average monthly sales exceeded $93,000 during this period, rising to more than $108,000 per month over the last three months. This growth is driven by adoption across major Greek hospital groups and a consistent pattern of repeat ordering. The company projects that this momentum will result in annualized gross profit of approximately $0.9 million.

Product Profile and Market Application

C-Sept PRO is a professional-grade antiseptic alcohol solution that combines 2% w/v chlorhexidine gluconate with 76% w/v isopropyl alcohol. The solution is fast-acting within one minute and offers wide-spectrum activity against gram-positive and gram-negative bacteria, viruses, and fungi. The alcohol component delivers rapid initial action, while chlorhexidine provides prolonged activity on the skin, even in the presence of biological fluids.

In hospital settings, C-Sept PRO is indicated for surgical and daily hand disinfection, pre-operative skin disinfection, skin preparation for injections and venipunctures, and skin disinfection prior to vascular catheterization. The product is available in formats ranging from 250 ml to 20 L to accommodate various clinical needs.

Strategic Outlook and Expansion

Cosmos Health views its hospital business as a new, high-margin revenue generator that combines attractive economics with revenue visibility due to recurring demand. The company intends to leverage Cana Laboratories' European GMP-certified manufacturing platform and its established distribution footprint to extend the hospital-focused antiseptics business into additional European markets over time.

Greg Siokas, CEO of Cosmos Health, stated that the accelerating momentum demonstrates the strength of the company's proprietary antiseptics franchise. He highlighted the opportunity to scale further across Greece and expand the hospital business into other European markets, citing the product's strong recurring demand and high margins.